178 related articles for article (PubMed ID: 36071927)
1. Magnetic resonance spectroscopy outperforms perfusion in distinguishing between pseudoprogression and disease progression in patients with glioblastoma.
El-Abtah ME; Talati P; Fu M; Chun B; Clark P; Peters A; Ranasinghe A; He J; Rapalino O; Batchelor TT; Gilberto Gonzalez R; Curry WT; Dietrich J; Gerstner ER; Ratai EM
Neurooncol Adv; 2022; 4(1):vdac128. PubMed ID: 36071927
[TBL] [Abstract][Full Text] [Related]
2. Three-dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma.
Verma G; Chawla S; Mohan S; Wang S; Nasrallah M; Sheriff S; Desai A; Brem S; O'Rourke DM; Wolf RL; Maudsley AA; Poptani H
NMR Biomed; 2019 Feb; 32(2):e4042. PubMed ID: 30556932
[TBL] [Abstract][Full Text] [Related]
3. Pseudoprogression in GBM versus true progression in patients with glioblastoma: A multiapproach analysis.
Sidibe I; Tensaouti F; Gilhodes J; Cabarrou B; Filleron T; Desmoulin F; Ken S; Noël G; Truc G; Sunyach MP; Charissoux M; Magné N; Lotterie JA; Roques M; Péran P; Cohen-Jonathan Moyal E; Laprie A
Radiother Oncol; 2023 Apr; 181():109486. PubMed ID: 36706959
[TBL] [Abstract][Full Text] [Related]
4. Myo-Inositol Levels Measured with MR Spectroscopy Can Help Predict Failure of Antiangiogenic Treatment in Recurrent Glioblastoma.
El-Abtah ME; Wenke MR; Talati P; Fu M; Kim D; Weerasekera A; He J; Vaynrub A; Vangel M; Rapalino O; Andronesi O; Arrillaga-Romany I; Forst DA; Yen YF; Rosen B; Batchelor TT; Gonzalez RG; Dietrich J; Gerstner ER; Ratai EM
Radiology; 2022 Feb; 302(2):410-418. PubMed ID: 34751617
[TBL] [Abstract][Full Text] [Related]
5. ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy.
Ratai EM; Zhang Z; Fink J; Muzi M; Hanna L; Greco E; Richards T; Kim D; Andronesi OC; Mintz A; Kostakoglu L; Prah M; Ellingson B; Schmainda K; Sorensen G; Barboriak D; Mankoff D; Gerstner ER;
PLoS One; 2018; 13(6):e0198548. PubMed ID: 29902200
[TBL] [Abstract][Full Text] [Related]
6. Distinguishing Tumor Recurrence From Radiation Necrosis in Treated Glioblastoma Using Multiparametric MRI.
Feng A; Yuan P; Huang T; Li L; Lyu J
Acad Radiol; 2022 Sep; 29(9):1320-1331. PubMed ID: 34896001
[TBL] [Abstract][Full Text] [Related]
7. Validation of multiparametric MRI based prediction model in identification of pseudoprogression in glioblastomas.
de Godoy LL; Mohan S; Wang S; Nasrallah MP; Sakai Y; O'Rourke DM; Bagley S; Desai A; Loevner LA; Poptani H; Chawla S
J Transl Med; 2023 Apr; 21(1):287. PubMed ID: 37118754
[TBL] [Abstract][Full Text] [Related]
8. Comparison of unsupervised classification methods for brain tumor segmentation using multi-parametric MRI.
Sauwen N; Acou M; Van Cauter S; Sima DM; Veraart J; Maes F; Himmelreich U; Achten E; Van Huffel S
Neuroimage Clin; 2016; 12():753-764. PubMed ID: 27812502
[TBL] [Abstract][Full Text] [Related]
9. Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma.
Chawla S; Bukhari S; Afridi OM; Wang S; Yadav SK; Akbari H; Verma G; Nath K; Haris M; Bagley S; Davatzikos C; Loevner LA; Mohan S
NMR Biomed; 2022 Jul; 35(7):e4719. PubMed ID: 35233862
[TBL] [Abstract][Full Text] [Related]
10. The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma.
Xi J; Hassan B; Katumba RGN; Khaddour K; Govindan A; Luo J; Huang J; Campian JL
BMC Cancer; 2021 Mar; 21(1):285. PubMed ID: 33726710
[TBL] [Abstract][Full Text] [Related]
11. Quantification of diagnostic biomarkers to detect multiple sclerosis lesions employing (1)H-MRSI at 3T.
Vafaeyan H; Ebrahimzadeh SA; Rahimian N; Alavijeh SK; Madadi A; Faeghi F; Harirchian MH; Rad HS
Australas Phys Eng Sci Med; 2015 Dec; 38(4):611-8. PubMed ID: 26526449
[TBL] [Abstract][Full Text] [Related]
12. Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis.
Rock JP; Hearshen D; Scarpace L; Croteau D; Gutierrez J; Fisher JL; Rosenblum ML; Mikkelsen T
Neurosurgery; 2002 Oct; 51(4):912-9; discussion 919-20. PubMed ID: 12234397
[TBL] [Abstract][Full Text] [Related]
13. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
[TBL] [Abstract][Full Text] [Related]
14. Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological, and Molecular Features.
Li M; Ren X; Dong G; Wang J; Jiang H; Yang C; Zhao X; Zhu Q; Cui Y; Yu K; Lin S
Front Oncol; 2021; 11():627325. PubMed ID: 33959496
[No Abstract] [Full Text] [Related]
15. A deep learning model for discriminating true progression from pseudoprogression in glioblastoma patients.
Moassefi M; Faghani S; Conte GM; Kowalchuk RO; Vahdati S; Crompton DJ; Perez-Vega C; Cabreja RAD; Vora SA; Quiñones-Hinojosa A; Parney IF; Trifiletti DM; Erickson BJ
J Neurooncol; 2022 Sep; 159(2):447-455. PubMed ID: 35852738
[TBL] [Abstract][Full Text] [Related]
16. Multisection 1H magnetic resonance spectroscopic imaging assessment of glioma response to chemotherapy.
Balmaceda C; Critchell D; Mao X; Cheung K; Pannullo S; DeLaPaz RL; Shungu DC
J Neurooncol; 2006 Jan; 76(2):185-91. PubMed ID: 16151595
[TBL] [Abstract][Full Text] [Related]
17. Measurements of diagnostic examination performance using quantitative apparent diffusion coefficient and proton MR spectroscopic imaging in the preoperative evaluation of tumor grade in cerebral gliomas.
Server A; Kulle B; Gadmar ØB; Josefsen R; Kumar T; Nakstad PH
Eur J Radiol; 2011 Nov; 80(2):462-70. PubMed ID: 20708868
[TBL] [Abstract][Full Text] [Related]
18. Role of Dynamic Susceptibility Contrast Perfusion MRI in Glioma Progression Evaluation.
Quan G; Zhang K; Liu Y; Ren JL; Huang D; Wang W; Yuan T
J Oncol; 2021; 2021():1696387. PubMed ID: 33628239
[TBL] [Abstract][Full Text] [Related]
19. Value of Proton-MR-Spectroscopy in the Diagnosis of Temporal Lobe Epilepsy; Correlation of Metabolite Alterations With Electroencephalography.
Aydin H; Oktay NA; Kizilgoz V; Altin E; Tatar IG; Hekimoglu B
Iran J Radiol; 2012 Mar; 9(1):1-11. PubMed ID: 23329953
[TBL] [Abstract][Full Text] [Related]
20. Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI.
Wang S; Martinez-Lage M; Sakai Y; Chawla S; Kim SG; Alonso-Basanta M; Lustig RA; Brem S; Mohan S; Wolf RL; Desai A; Poptani H
AJNR Am J Neuroradiol; 2016 Jan; 37(1):28-36. PubMed ID: 26450533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
